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Conclusions. Bevacizumab plus irinotecan in recurrent HGA improves responses, PFS and OS compared with historical data with
low toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.123
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Introduction. Clival chordomas are a rare, locally destructive and slow growing bone tumors that arise from vestiges of the noto-
chord. In adults, about 30% of chordomas occur at the base of the skull. Clival chordomas have a high rate of recurrence and have
rarely been reported to metastasize, this feature and the difﬁculty to achieve tumoral complete resection makes local progression
the most common cause of death. Case description. A 54-year old Caucasian man presented a progressive visual loss of the left
eye during one year. MRI reported a sellar and suprasellar mass of 23mm×24mm×27mm in intimate contact with the optic
chiasm and the third ventricle ﬂoor that deformes the anterior midbrain. Intraoperative exploration and pathological ﬁndings
revealed a clival chordoma. The patient underwent neurosurgery for the ﬁrst time on April 2010. On April 2011 he underwent
surgery again with partial resection because we found a suprasellar relapse of about 29mm×32mm×38mm and radiotherapy
with proton beam therapy was performed as adyuvant treatment on august 2011 in Switzerland. On February 2012 he presented
some behavioral and cognitive disorders and the MRI showed a bilateral hippocampal signal alterations that were ﬁnally diag-
nosed as radionecrosis, a side effect of the proton therapy. The symptoms were resolved with high doses of corticosteroids and
neurological and neuropsychological assessment was made too.
Conclusions. Proton beam therapy is an effective treatment for the local control of clival chordomas, especially for those patients
with small tumors. Despite successful control of these tumors, side effects such radiation necrosis are still a concern.
http://dx.doi.org/10.1016/j.rpor.2013.03.124
Combined treatment of malignant gliomas. A single center experience
S. Marcos1, R. Hernanz1, E. Fernandez1, A. Abondano1, M. Salgueiro1, D. Ordon˜ez1, J. Dominguez1, A. Ramos2
1 Hospital Ramón y Cajal, Oncologia Radioterapica, Spain
2 Hospital Ramón y Cajal, Oncolgia Radioterapica, Spain
Objectives. This retrospective analysis was performed to determinate the efﬁcacy, safety and feasibility of concurrent
radiochemotherapy (CRCT) followed by adjuvant chemotherapy with temozolomide (TMZ) in the treatment of patients with
malignant gliomas.
Methods. From July 2002 to August 2012, 96 patients with pathologically conﬁrmed malignant glioma were included in this
retrospective analysis. Median age was 62 years (range 27–80 years). Gender: male 61.5%, female 38.5%. The main tumor locations
were frontal or temporal lobe in 59.4% of cases. Preoperative ECOG: 0–1 for 88.5% of the patients. All but 3 patients (96.9%)
underwent surgery (complete resection in 57.3%) and 71.9% of the patients received treatmentwith corticosteroids. CRCT:median
dose of 60Gy (range 30–60Gy) in daily fractions of 2Gy, 5 days per week, for 6 week combined with TMZ (75mg/m2) per day.
Adjuvant chemotherapy: TMZ (150–200mg/m2) up to a median number of 6 (range 0–20) courses.
Results. With a median of follow-up of 43.5 months (range 8–128 months), median survival time was of 10.5 months with actuarial
1 and 2 years overall survival rates of 47.3% and 16.7% respectively. CCRT resulted in grade 3/4 hematologic toxicity in 2.1% of
patients. No cases of grade 5 toxicity were observed. Univariate analysis revelled that the signiﬁcant prognostic factors for overall
survival were: ECOG performance status 0–1 (p<0.00001), age at diagnoses below 60 years (p<0.033), complete tumor resection
(p<0.02), total dose of 60Gy (p<0.0001), concomitant TMZ (p<0.003), adjuvant TMZ (p<0.0001) and absence of corticosteroids
intake (p<0.025).
Conclusion. Combination of TMZ and radiotherapy for newly diagnosed malignant gliomas resulted in a clinically meaningful
and statistically signiﬁcant survival beneﬁt with minimal additional toxicity. Our results were similar to those reported in the
literature.
http://dx.doi.org/10.1016/j.rpor.2013.03.125
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Introduction. Cranio-Spinal Irradiation (CSI) is technically very challenging, historically ﬁeld edge matching is needed because of
the mechanical limitations of standard linear accelerators.
